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THE time course of effect of the B2-receptor agonist kalli-
din (K) on induced changes of nasal airflow, rhinorrhoea,
nasal pain, sneezing and nasal microvascular leakage has
been examined and compared with its B2 metabolite agon-
ist bradykinin (B) and the Bl-agonist [des-argg]-bradyki
nin (D). When administered as a single dose K and B
induced an immediate sensation of pain, rhinorrhoea,
elevations in lavage albumin and protein levels and a
sustained increase in nasal airways resistance (NAR) for
5-40 min post-challenge. [des-argg]-Bradykinin and ve-
hicle placebo (V) were without effect on any of these
indices. These studies identify the action ofK and B within
the nose and differentiate the neural and vascular effects
of these kinins in addition to suggesting the potential that
nasal blockage and nasal microvascular leakage represent
alterations in differing vascular compartments. These find-
ings have implications for the understanding and thera-
peutic manipulation of rhinitis.
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Introduction
The introduction of potent and specific HI-
antihistamines in the 1940s, confirmed histamine as
an important mediator of allergic rhinitis but, in
producing only partial relief of symptoms, revealed
the participation of other mediators in this disease.
Among these are the kinins, including, bradykinin
and kallidin (lysyl bradykinin), both of which are
potent vasoactive peptides formed as cleavage
products from the action of kallikreins on high and
low molecular weight kininogens respectively.
Metabolism of bradykinin occurs with cleavage of
the N-terminal [des-arg9] residue to a peptide which
is reported to be active on the B-receptor subtype.
2
The presence of increased kinin recovery by nasal
lavage during the early
3 and late4 phases of
allergen-provoked rhinitis and also in naturally
occurring rhinitis provides evidence that kinin
generating systems are operative in this disease and
their involvement in symptom generation is
suggested from nasal challenge studies. Nasal
insuflqation with bradykinin elicits many of the
clinical features of rhinitis including nasal blockage,
rhinorrhoea and increased micro-vascular leak-
age. 6’7 Less is known, however, of the nasal effects
of kallidin.
Kallidin comprises approximately half of the
amount of kinin recovered following nasal allergen
challenge
3 and accords with the finding of increased
tissue kallikrein in lavage fluid. Concordant with
this, elevated levels of aminopeptidase, capable of
converting kallidin to bradykinin, have been
demonstrated in post-allergen challenge nasal
lavage.
9 Bradykinin and kallidin both produce nasal
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blockage by interacting with the B2-receptor
subtype and are of comparable potencies when
given in incremental doses. 7 However, in the lower
airways, kallidin is about three times lss potent as
a bronchoconstrictor than bradykinin in molar
terms.
10
To further explore the comparative range of
effects of kallidin within the nose, the time course
of action of this kinin on individual nasal symptoms
and signs has been studied in parallel with
comparable amounts of the nasal effects of the B2
agonist bradykinin and the B agonist [des-argg]
bradykinin in healthy volunteers.
Subjects and Methods
The study was conducted in eight non-rhinitic,
non-atopic healthy volunteers (six males and two
females) with a mean age of 29 years. All subjects
refrained from taking any medications throughout
the study period. None of the subjects had a history
of recent upper respiratory tract infection, nasal
polyps, infective rhinitis, nasal surgery or nasal
deformities and all gave written informed consent.
The study was approved by the Southampton
hospitals and University joint ethical subcommittee.
The study was conducted in three phases.
Phase I: Subjects attended on four occasions at the
same time of the day to receive nasal challenge with
incremental doses of either bradykinin, kallidin,
[des-argg]-bradykinin or vehicle placebo in a
doubl’e-blind cross-over manner. The objective
response parameter was nasal airways resistance
(NAR). At each visit, subjects were rested for 15
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min and baseline measurements ofNAR were made
by active posterior rhinomanometry using a
Mercury NR6 Rhinomanometer (Mercury instru-
ments, Glasgow, Scotland) as described previously.
7
The measurement of NAR has a coefficient of
variation of repeated measurements of 10.7%.
Providing the baseline values ofNAR did not vary
by > 10%, subjects then underwent nasal challenge
with vehicle followed by incremental doses of either
bradykinin, kallidin, [des-arg9]-bradykinin or
vehicle placebo at 20 min intervals until the top
challenge dose had been achieved. The three kinins
(Nova Biochem Ltd, Nottingham, UK) were
dissolved in ethanol (10%) and 0.9% sodium
chloride to produce concentrations of 0.077, 0.77,
3.85 and 7.7 mg/ml. These doses were chosen from
previous studies. 6’7 The purity of the synthetic
kinins was confirmed by high-performance liquid
chromatography (HPLC) as described previously.
Nasal challenge was undertaken bilaterally using a
hand-held pump spray delivering 0.13ml per
activation with a coefficient of variation of output
of 8.4%. The spray was placed in one nostril while
occluding the other and activated once during quiet
inspiration. The procedure was then repeated in the
opposite nostril. At the concentrations employed,
this method delivered total kinin doses of 20, 200,
1 000 and 2 000g equally divided between the two
nostrils. After each challenge repeat measurements
of NAR were made at 3, 5, 10, 15 and 20 min
post-challenge.
Phase 2: To investigate the time course of effect of
nasal insufflation with kinins on induced symptoms
and signs, each of the eight subjects attended at the
same time of the day on four further occasions
separated by at least 7 days to receive nasal chal-
lenge with a single dose (2 000 #g) of bradykinin,
kallidin, [des-arg9]-bradykinin or vehicle in a
double-blind crossover manner. Repeat measure-
ments of NAR were made at 3, 5, 10, 15, 20, 25,
30, 35 and 40 min post-challenge. Subjects also
recorded their symptom of nasal pain/discomfort on
a 10 cm visual analogue scale, before and at 3, 5,
10, 15, 20, 25, 30, 35 and 40 min post-challenge.
Rhinorrhoea was measured 45 s before each of these
time points by asking the subjects to blow
secretions into a pre-weighed tissue towel. The
tissue towels were then immediately reweighed and
the weight of secretion calculated by subtraction.
The symptom of sore throat was recorded as
present or absent and the number of sneezes
following challenge was counted.
Phase 3: To investigate the time-course of action of
these kinins on nasal vascular permeability, each of
the eight subjects attended on an additional four
occasions, and were randomly allocated to receive
nasal challenge with the same single dose of
bradykinin, kallidin, [des-arg]-bradykinin or
vehicle as for phase 2, in a double-blind, cross-over
study design. At each attendance sequential nasal
lavage was performed bilaterally five times, at 1-min
intervals, prior to nasal insufflation challenge.
Subjects were instructed to tilt their heads
backwards about 30 from the horizontal while in
the sitting position, to hold their breath and refrain
from swallowing. Two and a half ml of 0.9%
prewarmed saline was instilled into each nostril and
after 10 s subjects flexed their necks and expelled
the mixture of airways surface liquid and saline into
a collection vessel. Nasal lavage was then repeated
at 3, 5, 10, 15, 20, 25, 30, 35 and 40 min after each
of the nasal challenges,
Analysis of nasal lavage )quid: Lavage samples were
immediately stored on ice until the conclusion of
the experiments when they were frozen at --20C
to await protein analysis. After thawing at room
temperature, total protein concentrations were
measured in 0.25 ml replicates by the method given
by Bradford
11 using Coomassie Blue G-250 reagent
(Pierce, Rockford, IL, USA) as indicator. Absor-
bance read at 595 nm was compared with a standard
curve constructed with bovine serum albumin
(Sigma, Poole, UK) to give absolute protein
concentrations.
Albumin concentrations were measured by
rocket immunoelectrophoresis.
12 Three microlitre
aliquots of nasal lavage fluid were introduced into
wells cut in agarose gel and subjected to
electrophoresis (4 V/cm) for 20 h into a ’window’
of agarose containing 1.18ktl/cm
2 of rabbit
anti-human albumin antibody (Nordic, Tilburg,
Netherlands). Immunoprecipitates were stained
with Coomassie Brilliant Blue. Albumin levels were
quantified by comparison with standard curves
constructed using human serum albumin (Sigma,
Poole, UK). The sensitivity of the albumin assay
was 1 #g/ml and the coefficient of variation of
repeated measurements is 5%.
Data anasis: On the different challenge days baseline
measurements of NAR, lavage albumin and total
protein were compared using the Friedman’s
two-way ANOVA test. The time-dependent
changes in NAR (Pa/cm3s), lavage albumin and
total protein were compared both within groups
and between groups using Friedman’s test. To
assess differences between treatments, the mean area
under the curve (AUC) for each time period of
observation was calculated and compared using the
Wilcoxon’s signed rank test for paired data. The
Wilcoxon’s signed rank test was also used for
comparisons of the challenges on the quantity of
nasal secretions, the number of sneezes and the
visual analogue scores for nasal pain. Values are
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expressed as mean-F standard error of mean or
median values with ranges.
Results
Phase 1: There were no significant differences
between the baseline NAR measurements in the
eight subjects on any of the four challenge days
(p > 0.05). Both bradykinin and kallidin caused a
dose-dependent increase in NAR (p < 0.01),
while [des-argg]-bradykinin and vehicle were
without significant effect (Fig. 1). There was no
significant difference in the eects of bradykinin
and kallidin on NAR at any dose level > 0.05)
whether assessed as peak response or area under
the curve.
Phase 2: There were no signifi’cant differences
between baseline N.AR measurements in the eight
subjects on any of the four challenge days
(p > 0.05). Insuf]:lation of vehicle had no signifi-
cant effect on NAR. Bradykinin administered as a
single dose of 2000/g caused a rapid increase in
NAR reaching maximum of 71.4% above baseline
at 15 min (p < 0.05) and gradually declining over
40 min to 50.0% above baseline (Fig. 2). Kallidin
also increased NAR by a median maximum of
57.1% (p < 0.05). This peak was reached 20 min
post-challenge. The increase in NAR with challenge
was significantly greater for bradykinin than
kallidin at 5 and 15 min post-challenge but
thereafter there was no significant difference from
that seen with bradykinin (Fig. 2). However, there
was no significant difference between the areas
under the time-response curves for both agonists
(p > 0.05). The increase in NAR was significantly
greater than the pre-challenge measurements from
3 to 40 min (p < 0.05). In contrast [deg-argg]-brady
kinin produced no significant change in NAR.
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FIG. 1. Dose-dependent changes in NAR following nasal challenge with
incremental doses (20, 200, 000 and 2 000 #g) of bradykinin (O),
kallidin (/k), [des-argg]-bradykinin (V) and 10% ethanol saline (O).
Each result is the median of observations in eight subjects.
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FIG. 2. NAR changes following nasal challenge with single dose of
bradykinin 2 000 #g (O), kallidin 2 000 #g (/k), rdes-arg9]-bradykinin
2 000 #g (V) and 10% ethanol saline (O). Each result is the median of
observations in eight subjects.
When compared with vehicle, bradykinin and
kallidin, but not [des-argg]-bradykinin, produced
rhinorrhoea, with median total secretion weights of
376 (range 179-597) mg and 330 (range 60-
1351) mg, respectively (p < 0.05). The increase in
nasal secretions was maximum 3 min post-challenge
and declined rapidly to very low levels,
indistinguishable from placebo, by 20 min post-
challenge (Fig. 3A). Both bradykinin and kallidin
produced similar degrees of nasal pain, with median
(range) values of 3.45 (range 0.6-7.2)cm and 3.4
(range 0-7.5)cm, respectively (p < 0.05). Nasal
pain reached maximum at 3 min post-challenge and
lasted for 5 rain (Fig. 3B). Neither [des-argg]
bradykinin nor vehicle produced algesic effect (Fig.
3B). None of the subjects complained of nasal itch
and following bradykinin and kallidin challenge
three subjects complained of sore throat lasting up
to 25 min. None of the subjects sneezed following
kinin nasal challenge.
Phase 3" There were no significant difference
between the fifth baseline nasal lavage albumin
levels in the eight subjects on the four challenge
days, the group means being 24.73 5.71,
26.14-F 10.1, 27.71 -F 12.9 and 27.7-F 9.14 #g/ml
for subjects receiving bradykinin, kallidin, [des-
arg9]-bradykinin and vehicle, respectively. InsuflCla
tion with bradykinin and kallidin increased the
concentration of albumin recovered in the nasal
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FIG. 3. Effects of bradykinin 2 000 #g (O), kallidin 2 000 #g (/k), [des-argS]-bradykinin 2 000 #g (V) and 10% ethanol saline vehicle
((C)) on (A) rhinorrhoea, (B) nasal pain. Each result is the median of observations in eight subjects.
lavage (p < 0.05) (Fig. 4A). On repeated lavage,
maximum albumin concentration achieved with
both challenges occurred within 10 min and
decayed progressively to baseline by 40 min (Fig.
4A). By contrast nasal challenge with [des-arg9]
bradykinin and vehicle failed to induce significant
changes in lavage albumin concentration (Fig. 4A).
There were no significant differences between the
fifth baseline nasal lavage total protein levels in the
eight subjects on the four challenge days, the group
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FIG. 4. Nasal lavage (A) albumin and (B) total protein changes following nasal challenge with single dose of bradykinin 2 000 #g (O), kallidin 2 000/g
(/k), [des-argS]-bradykinin 2 000 #g (V) and 10% ethanol saline ((C)). Each result is the mean +__ S.E. of mean of observations in eight subjects.
220 Mediators of Inflammation. Vol 2.1993Nasal responses to kinins
means being 121.58 _--+- 40.14, 101.54 23.12,
67.25 __+ 8.63 and 90.25 -+- 20.88 #g/m1 for sub-
jects receiving bradykinin, kallidin, [des-arg9]
bradykinin and vehicle, respectively. When com-
pared to vehicle, both bradykinin and kallidin
induced significant increases in lavage total protein
levels (p < 0.05) with a time course similar to that
seen with albumin whereas [deg-argg]-bradykinin
had no effect (Fig. 4B). The albumin and total
protein responses following bradykinin and kallidin
were not significantly different when compared
using the AUC (p > 0.05).
Discussion
This study extends and confirms our previous
findings that Be-agonists bradykinin and kallidin
induce a dose-dependent increase in nasal airways
resistance while the Bl-agonist [des-arg9]-bradyki
nin is without effect. 7 By selecting equi-doses of
kallidin and bradykinin it has been possible to
further explore their time course of action and to
investigate their relative effects not only on nasal
blockage but also on nasal pain, sneezing,
rhinorrhoea and on increments in nasal lavage
albumin and total protein levels. Both kallidin and
bradykinin but not [des-arg9]-bradykinin induced
changes in all these indices with the exception of
sneezing.
Within human lower airways kallidin is three
times less potent than bradykinin as a bronchocon-
strictor when these kinins are compared on a molar
basis.1 In contrast we have previously found that
kallidin and bradykinin, when administered in
incremental doses, to be approximately equipotent
in the nasal obstructive effect within the upper
airways.
7 Similar differences have been reported in
other species and our finding is not inconsistent
with other studies where bradykinin and kallidin
have been shown to have varying potency of
action.3’4 In rats, kallidin has been shown to be
more potent than bradykinin in causing relaxation
of isolated smooth muscle preparation from
duodenum, although on isolated smooth muscles
from guinea-pig ileum and rat uterus a reversed
order of potency has been observed.
3 Kallidin is
also more potent than bradykinin as a local
vasodilator in dogs.
4 In the canine tracheal
epithelium, which is enriched in kinin receptors,
kallidin is equipotent with bradykinin in inducing
chloride secretion, is The relevance of such a
consideration to rhinitis is the identification that
kallidin represents 45% of the total kinin pool in
lavage fluid following nasal allergen challenge.
Single dose nasal administration of both kallidin
and bradykinin but not [des-argg]-brady-kinin
induced a significant increase in nasal airways
resistance. For each of the B2-receptor agonists this
was significant from 5 to 40 min post-challenge
(Fig. 2). Although the effect of bradykinin appears
greater than that of kallidin there was no significant
difference between the areas under the time-
response curves for both agonists. However, when
compared at individual time points, the NAR
increase following bradykinin nasal challenge was
significantly greater at 5 and 15 min post-challenge.
The peak NAR responses following kallidin and
bradykinin were at 20 and 15 min post-challenge,
respectively.
The present study also identifies that both
kallidin and bradykinin induce nasal pain, rhi-
norrhoea, nasal blockage and an increase in nasal
lavage protein levels. These are the first human
studies investigating in detail these neural and
vascular mediated effects of kallidin within the nose.
The nasal blockage and increase in lavage protein
levels are considered to be manifestations of direct
vascular actions. Inconsistent with this, kinin
B2-receptors have been localized to the vasculature
of the nasal mucosa,
6 and the nasal obstructive
response, but not the plasma protein exudation, has
been shown to be prevented by prior administration
of the -adrenergic agonist oxymetazoline. It is
therefore likely that nasal obstruction and plasma
protein extravasation represent different vascular
mechanisms. Consistent with this, the time course
of increase in lavage protein levels which peaks at
10 min and resolves within 20 min post-challenge
differs from the time course of effect on nasal
airflow, further suggesting that the nasal blockage
and plasma protein leakage are two independent
vascular effects (Figs 2 and 4). Nasal obstruction
arises from engorgement of venous plexi within the
turbinates.
8 These plexi are under sympathetic
regulation and factors which increase sympathetic
stimulation (i.e., exercise, 0-adrenergic agonists)
increase nasal airflow and reduce nasal airways
resistance whereas mediators, such as histamine,
prostaglandins and kinins which have direct
vasodilator properties induce nasal obstruction.
In addition, laser doppler flowmetry studies have
identified changes in blood flow in the superficial
mucosal vasculature following bradykinin challenge
(Rajakulasingam K, unpublished findings). This is
not always in concordance with the nasal
obstructive response and it is likely that endothelial
contraction with opening of gap junctions in
post-capillary venules present beneath the basement
membrane and around glands in the nasal mucosa,
are responsible for the increase in lavage protein
levels.
9 Consistent with this, changes in vascular
permeability produce unrestricted plasma molecular
leak, concordant with the albumin and total protein
increments in lavage with kallidin and bradykinin.
Although it is not possible to exclude glandular
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secretion of protein, this is less likely as our study
shows that the predominant protein in nasal lavage
is albumin (Fig. 4), a plasma protein synthesized by
liver and no Be-receptors have been localized to
glandular structures within the human nose.
16 The
neural effects of kinin insufflation are pain and
possibly rhinorrhoea. With histamine nasal insutTla-
tion the rhinorrhoea is bilateral following unilateral
challenge and can be inhibited by antimuscarinic
pretreatment indicative of a reflex vagal mechan-
ism.2
In a separate investigation we have been unable
to identify any protective effect of nasal ipratropium
bromide on bradykinin induced rhinorrhoea.
21 This
suggests that the mechanism of rhinorrhoea with
bradykinin differs from histamine. Consistent with
this the sensory neural stimulation induced by
kallidin and bradykinin differs from histamine is not
inducing sneezing. Thus the nasal pain induced by
kinins must reflect different sensory neural
pathways than those stimulated by histamine. That
these nerves are distinct from the classical
unmyelinated ’C’ sensory nerves is further
suggested by the identification that the ipsilateral
secretory effects of unilateral capsaicin nasal
challenge are blocked by the coadministration of
intramuscular atropine and topical ipratropium
bromide
22 and that repeated nasal capsaicin
pretreatment has failed to diminish the algesic
response to kallidin.
23 This indicates that the human
nose differs from animals in its response to kinins,
as the effects of bradykinin in canine and rat airways
have been shown to be mediated via capsaicin
sensitive, sensory neurones,24’25 and further high-
lights the interspecies differences in response to
kinins.
It is possible that the rhinorrhoea induced by
kallidin and bradykinin which peaks at the same
time as the nasal pain following challenge (Fig. 3)
represents stimulation of neuropeptide containing
nerves with consequent peptide release and
glandular secretion. Alternatively, as bradykinin has
been reported to stimulate prostaglandin synth-
esis26’27 it is possible that this could account for the
nociceptive and secretory effects of kallidin and
bradykinin. Against such a possibility is the rapidity
of onset of the algesic effect, and the recent report
that oral acetyl salicylic acid had no effect on the
nasal discomfort following nasal bradykinin chal-
lenge.
17 A further possibility is that the rhinorrhoea
is a reflection of plasma leakage rather than
glandular secretion. While studies in cats and ferrets
have indicated that apparent secretion induced by
bradykinin is not associated with an increase in
mucous glycoconjucates
16 the rapid increase in
rhinorrhoea observed in this study, which occurred
before marked increases in lavage albumin were
observed, would argue against such a possibility.
Thus the exact mechanism of the rhinorrhoea
remains to be elucidated.
In conclusion this study draws attention to the
vascular actions of kallidin and bradykinin within
the nose and indicates that obstruction and vascular
permeability represent distinct entities. The pro-
longed action of these kinins on nasal obstruction
suggests their importance in clinical disease.
However, the contribution of kinins to the
symptomatology of rhinitis will not be fully
elucidated until potent and selective inhibitors of
kinin generation or antagonists of kinin receptor
mediated effects become available.
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